Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 209.17M P/E - EPS this Y -22.60% Ern Qtrly Grth -
Income -88.56M Forward P/E -2.73 EPS next Y 2.40% 50D Avg Chg -19.00%
Sales - PEG -0.23 EPS past 5Y - 200D Avg Chg 28.00%
Dividend N/A Price/Book 2.01 EPS next 5Y 13.10% 52W High Chg -35.00%
Recommedations 1.60 Quick Ratio 9.30 Shares Outstanding 67.10M 52W Low Chg 379.00%
Insider Own 0.51% ROA -37.87% Shares Float 35.02M Beta 1.52
Inst Own 97.74% ROE -88.56% Shares Shorted/Prior 3.93M/3.96M Price 4.75
Gross Margin - Profit Margin - Avg. Volume 617,506 Target Price 19.00
Oper. Margin - Earnings Date Nov 5 Volume 604,578 Change -5.38%
About Inozyme Pharma, Inc.

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Inozyme Pharma, Inc. News
11/13/24 Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
11/11/24 Inozyme Pharma to Present at Upcoming Investor Conferences
11/05/24 Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
10/24/24 Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
10/17/24 Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024
10/07/24 Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
09/26/24 Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
08/29/24 Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
08/18/24 Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks
08/11/24 Institutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term losses
08/06/24 Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
07/25/24 Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
07/02/24 Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
06/29/24 Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?
12:00 PM Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
05/30/24 Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
05/23/24 Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
05/08/24 Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
05/07/24 Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
05/03/24 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INZY Chatroom

User Image Baltic_Roots Posted - 9 hours ago

$INZY my goodness 😳 I sold this one at 5.35 and after this went to $ 8 , crazy price now ... just crazy and still trading over cash

User Image TeeMan123 Posted - 1 day ago

$INZY CEO came across as really impressive at the Jefferies conference. Feels like this one is getting unfairly punished amid all the nomination noise. At the end of the day, if we’re looking at a more FDA-friendly environment specifically for rare diseases, their programs—especially given how critical they are for children—should have a much smoother path to approval. Curious to see who ultimately gets nominated for the top spot.

User Image TeeMan123 Posted - 1 day ago

$INZY CEO came across as really impressive at the Jefferies conference. Feels like this one is getting unfairly punished amid all the nomination noise. At the end of the day, if we’re looking at a more FDA-friendly environment for rare disease, their programs—especially given how critical they are for children—should have a much smoother path to approval. Curious to see who ultimately gets nominated for the top spot.

User Image AProst Posted - 1 day ago

$INZY This CEO reminds me of the CEO from Cymabay. Confident in his presentations. Confident in the ultimate goal. I choose to ride this one out. Stock price seems due to market, not leadership capabilities.

User Image Cesar_Stone Posted - 1 day ago

$INZY $OCGN $ABEO LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image FlymetotheMoon1738 Posted - 2 days ago

$INZY thoughts on any end to this madness?

User Image HopefulCass Posted - 2 days ago

$INZY $4.58 seems like dream land now 😕

User Image fulcrum Posted - 3 days ago

$INZY they will need to raise money before their data readout, which does not look favorable

User Image HopefulCass Posted - 3 days ago

$INZY somebody is pissed off I guess....

User Image AProst Posted - 1 week ago

$INZY ohhh please. This is not tanking. There is no volume to this drop and can go back to 6 dollars in an hour's time. Of all the bio I have, this is the most promising...and dont have to drink the "hopium" potion.

User Image HopefulCass Posted - 1 week ago

$INZY what the hell is going on with this thing. This has taken a hold of me and dragged me deeply under water. Why the sell off? Bad news incoming?

User Image AProst Posted - 1 week ago

$INZY OK. I dont mind playing the long game, and my posts show that. But, if this goes down to 3 dollars before it goes to 10 dollars...I am going to be pissed off. I am growing a bit frustrated with bio.

User Image Quantumup Posted - 2 weeks ago

Piper Sandler⬆️PT $INZY $43 was $40/OW, says it conts2model success4both ENPP1 / ABCC6, w/ calciphylaxis as a major unmodeled upside—Even if INZ-701 achieves success in only one of these indications, w/ the stock trading at <$5/sh, PS sees meaningful upside pot/remain buyers:

User Image HopefulCass Posted - 2 weeks ago

$INZY Q3 ER out today. Data coming before EOY.

User Image PenkeTrading Posted - 2 weeks ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Inozyme Pharma Inc. Is that bullish or bearish? $INZY #Inozyme #RsiOversold #NASDAQ

User Image KingNeptune Posted - 2 weeks ago

$INZY let's go! Just hopped in!

User Image AProst Posted - 10/30/24

$INZY The fact that no one is posting or responding tells me I am in the correct stock (again)....and not dealing with beer hall gamblers.

User Image AProst Posted - 10/29/24

$INZY 2 additional catalysts due this quarter...correct? Please confirm my reading of last Q report. Sure seems analysts like this past poster presentation. Thank you.

User Image HopefulCass Posted - 10/28/24

$INZY $4.58 in the PM? The hell???

User Image Charleslapi99 Posted - 10/24/24

Wow thanks Long again 100 share free Next is $TGTX $LXEO $PYXS $INZY bullish all bio

User Image BigBri217 Posted - 10/24/24

$INZY great news!

User Image justiceforb_85 Posted - 10/24/24

$INZY $XBI great news for patient's with ESRD at risk for calciphylaxis. This would increase the TAM significantly. https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-announces-positive-interim-data-phase-1-seaport-1

User Image AProst Posted - 10/24/24

$INZY new to comments...not new to stock. I dont think people realize how nice this is going to be if it bit them in the @ss. We shall see.

User Image HopefulCass Posted - 10/24/24

$INZY $TERN you are welcome amigo. Let's go!

User Image KingNeptune Posted - 10/23/24

$INZY so glad I'm in this before the presentation tomorrow. Should run from this cheap price. Cheers to the other guy that compared the feeling to how $TERN reacted after their news. Let's hope!

User Image Stocks4thought Posted - 1 month ago

$INZY sEXY AGAIN

User Image Sgv420 Posted - 1 month ago

$INZY - Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Participants with ESKD Undergoing Hemodialysis: Interim Analysis Poster Session – Clinical: Bone and Mineral Metabolism Thursday, October 24, 2024

User Image Doozio Posted - 1 month ago

$INCY $INZY 🧠⏰♾️

User Image tallguy777 Posted - 1 month ago

$INZY

User Image Doozio Posted - 1 month ago

$INZY tightness bahhhtom of da base as $incy wincy gets scrabble bagged in da FUTUre of 🧠⏰ which is NOW during 🧠⏰♾️

Analyst Ratings
Wedbush Outperform Sep 30, 24
Stifel Buy Sep 12, 24
HC Wainwright & Co. Buy Aug 8, 24
Needham Buy Aug 6, 24
Wedbush Outperform Jul 26, 24
HC Wainwright & Co. Buy Jul 2, 24
Wells Fargo Overweight May 30, 24
Needham Buy May 8, 24
Needham Buy Apr 10, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Pivotal bioVenture Partners Fu... Director Director Aug 01 Buy 4.8 833,333 3,999,998 1,571,741 08/03/23
Hopfner Robert Lorne Director Director Aug 01 Buy 4.8 833,333 3,999,998 1,571,741 08/03/23
Hopfner Robert Lorne Director Director May 11 Buy 6.37 447,932 2,853,327 3,661,518 05/15/23
Hopfner Robert Lorne Director Director Mar 29 Buy 4.5379 344,592 1,563,724 3,213,586 03/30/23
Hopfner Robert Lorne Director Director Mar 27 Buy 3.93 207,840 816,811 2,868,994 03/29/23
Bjarke Henric Bjorn SVP, COO SVP, COO Dec 15 Buy 1.39 21,500 29,885 105,441 12/19/22
Longitude Capital Partners III... 10% Owner 10% Owner Apr 19 Buy 3.69 1,355,000 4,999,950 4,174,379 04/21/22
Pivotal bioVenture Partners Fu... Director Director Apr 19 Buy 3.69 1,070,000 3,948,300 2,661,154 04/20/22
Bjarke Henric Bjorn SVP, COO SVP, COO Apr 19 Buy 3.69 27,100 99,999 80,626 04/20/22
Bolte Axel Chief Executive Offi.. Chief Executive Officer Apr 19 Buy 3.69 67,750 249,998 258,575 04/20/22
Hopfner Robert Lorne Director Director Apr 19 Buy 3.69 1,070,000 3,948,300 2,661,154 04/20/22
Subramanian Sanjay SVP, CFO SVP, CFO Apr 19 Buy 3.69 27,100 99,999 27,100 04/20/22